The newly developed CAR-T cell therapy has got huge breakthrough in hematological malignancies. However, this method still need to be improved in the treatment of solid tumors. Ovarian cancer is one of the gynecological cancers in clinical practice, and most patients are diagnosed in the late stage, and until now there is no targeted method to cure it. Therefore, it is important to apply the therapy that discussed in the treatment of OC to decrease the death rate. However, this therapy has certain limitations and its clinical application is not positive. Thus, the scientists combine the therapies with other therapies like PD-1 and PD-Ll axis or the immune checkpoint inhibitors. Finding appropriate targets like TAG-72 and CD47 is another approach to improve the therapy. Moreover, currently there are some limitations to strict the wide spread of the therapy, for instance, the high toxicity, the low infiltration and the lack of experimental data.
|